SuperworthCabaletta Bio EPS CABA
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.34
- Fiscal year 2021
- −$1.80
Cabaletta Bio's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.34.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2021 | −$1.80 | n/a |
| FY2020 | −$1.40 | n/a |
| FY2019 | −$10.42 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.34 | n/a | n/a | |
| Q1 FY26 | −$0.39 | n/a | n/a | |
| Q3 FY25 | −$0.44 | n/a | n/a | |
| Q2 FY25 | −$0.73 | n/a | n/a | |
| Q1 FY25 | −$0.71 | n/a | n/a | |
| Q3 FY24 | −$0.62 | n/a | n/a | |
| Q2 FY24 | −$0.56 | n/a | n/a | |
| Q1 FY24 | −$0.51 | n/a | n/a | |
| Q3 FY23 | −$0.37 | n/a | n/a | |
| Q2 FY23 | −$0.37 | n/a | n/a | |
| Q1 FY23 | −$0.45 | n/a | n/a | |
| Q3 FY22 | −$0.39 | n/a | −$1.78 |
Against its peers
Companies in Biotechnology nearest Cabaletta Bio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CABACabaletta Bio | n/m | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Cabaletta Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.